Ann: Mesoblast Update on COVID-19 ARDS Trial, page-624

Even when what you call "downrampers" pointed out that SOC had increased considerably since the early days compared to the controlled 12 patients trial, that we needed a lot if luck and for the placebo cohort to die for our mortality end point to be met, that ards was a golden egg, 1 in a million chance, that MSB should never have detoured to the ARDS route and should have stuck with their core business with aGVHD, CHF, CLBP it was all ignored. You only want to listen to what you want to hear. You don't want any negativity and so when you failed results you are shocked that none of this could possibly have been forecast. You were convinced all MSB products were going to be approved.

I'm sorry you lost out but you had many chances to reassess your holding from pre odac drop to agvhd rejection each time the SP recovered a decent amount.

For me I've picked up 20,000 shares today a stab at CLBP and CHF I'm interested to see what happens. These next few weeks to months is going to be interesting and the SP is reasonable for where we are.